These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24706855)

  • 1. Low-dose recombinant properdin provides substantial protection against Streptococcus pneumoniae and Neisseria meningitidis infection.
    Ali YM; Hayat A; Saeed BM; Haleem KS; Alshamrani S; Kenawy HI; Ferreira VP; Saggu G; Buchberger A; Lachmann PJ; Sim RB; Goundis D; Andrew PW; Lynch NJ; Schwaeble WJ
    Proc Natl Acad Sci U S A; 2014 Apr; 111(14):5301-6. PubMed ID: 24706855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective potency of recombinant meningococcal IgA1 protease and its structural derivatives upon animal invasion with meningococcal and pneumococcal infections.
    Kotelnikova O; Alliluev A; Zinchenko A; Zhigis L; Prokopenko Y; Nokel E; Razgulyaeva O; Zueva V; Tokarskaya M; Yastrebova N; Gordeeva E; Melikhova T; Kaliberda E; Rumsh L
    Microbes Infect; 2019; 21(7):336-340. PubMed ID: 30797878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent meningococcal septicaemia and properdin deficiency.
    Cunliffe NA; Snowden N; Dunbar EM; Haeney MR
    J Infect; 1995 Jul; 31(1):67-8. PubMed ID: 8522838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine.
    Fijen CA; Kuijper EJ; Drogari-Apiranthitou M; Van Leeuwen Y; Daha MR; Dankert J
    Clin Exp Immunol; 1998 Dec; 114(3):362-9. PubMed ID: 9844044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bactericidal activity for Neisseria meningitidis in properdin-deficient sera.
    Söderström C; Braconier JH; Danielsson D; Sjöholm AG
    J Infect Dis; 1987 Jul; 156(1):107-12. PubMed ID: 3110302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with meningococcal outer-membrane protein vesicles containing lipooligosaccharide protects mice against lethal experimental group B Neisseria meningitidis infection and septic shock.
    Quakyi EK; Frasch CE; Buller N; Tsai CM
    J Infect Dis; 1999 Sep; 180(3):747-54. PubMed ID: 10438363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial properdin deficiency and fatal meningococcemia. Correction of the bactericidal defect by vaccination.
    Densen P; Weiler JM; Griffiss JM; Hoffmann LG
    N Engl J Med; 1987 Apr; 316(15):922-6. PubMed ID: 3102964
    [No Abstract]   [Full Text] [Related]  

  • 8. Invasive bacterial diseases: national surveillance in Italy and vaccination coverage in the Local Health Agency 4 "Chiavarese", Liguria region (Italy).
    Trucchi C; Zoppi G
    J Prev Med Hyg; 2012 Jun; 53(2):120-4. PubMed ID: 23240174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
    Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ
    Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity.
    Welsch JA; Moe GR; Rossi R; Adu-Bobie J; Rappuoli R; Granoff DM
    J Infect Dis; 2003 Dec; 188(11):1730-40. PubMed ID: 14639545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The adhesin complex protein (ACP) of Neisseria meningitidis is a new adhesin with vaccine potential.
    Hung MC; Heckels JE; Christodoulides M
    mBio; 2013 Feb; 4(2):. PubMed ID: 23443003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live Meningococci.
    Li Y; Sun YH; Ison C; Levine MM; Tang CM
    Infect Immun; 2004 Jan; 72(1):345-51. PubMed ID: 14688114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with recombinant Chaperonin60 (Chp60) outer membrane protein induces a bactericidal antibody response against Neisseria meningitidis.
    Phillips R; Williams JN; Tan WM; Bielecka MK; Thompson H; Hung MC; Heckels JE; Christodoulides M
    Vaccine; 2013 May; 31(22):2584-90. PubMed ID: 23566947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Partial properdin deficiency revealed by a septicemia caused by Neisseria meningitidis].
    Frémeaux-Bacchi V; Le Coustumier A; Blouin J; Kazatchkine MD; Weiss L
    Presse Med; 1995 Sep; 24(28):1305-7. PubMed ID: 7501623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced protective responses to a serotype-independent pneumococcal vaccine when combined with an inactivated influenza vaccine.
    Babb R; Chen A; Ogunniyi AD; Hirst TR; Kara EE; McColl SR; Alsharifi M; Paton JC
    Clin Sci (Lond); 2017 Jan; 131(2):169-180. PubMed ID: 27885052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae.
    Agarwal S; Ferreira VP; Cortes C; Pangburn MK; Rice PA; Ram S
    J Immunol; 2010 Jul; 185(1):507-16. PubMed ID: 20530262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B.
    Moe GR; Zuno-Mitchell P; Lee SS; Lucas AH; Granoff DM
    Infect Immun; 2001 Jun; 69(6):3762-71. PubMed ID: 11349041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal Immunization with the Commensal
    Shekhar S; Khan R; Schenck K; Petersen FC
    Appl Environ Microbiol; 2019 Mar; 85(6):. PubMed ID: 30683742
    [No Abstract]   [Full Text] [Related]  

  • 19. Recombinant Neisseria surface protein A is a potential vaccine candidate against Neisseria meningitides serogroup B.
    Ying S; He J; Yu M; Zhang Y; Deng S; Zhang L; Xie M; Hu S
    Mol Med Rep; 2014 Sep; 10(3):1619-25. PubMed ID: 24926810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Universal vaccination against group C meningococci and pneumococci; advice from the Health Council of the Netherlands].
    van Furth AM; Vandenbroucke-Grauls CM
    Ned Tijdschr Geneeskd; 2002 May; 146(20):932-3. PubMed ID: 12051059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.